Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial
Clinical trial NCT07474324 · RECRUITING
Trial details
- NCT number
- NCT07474324
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-15
- Primary completion
- 2028-12-31
- Enrollment
- 124
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.